^
    Back
    Association details:
    Biomarker:PRKCB-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib

    Published date:
    12/01/2019
    Excerpt:
    A 44-year-old Chinese male smoker presented to our hospital for a cough that had persisted for 1 month….EML4-ALK (E6:A20) and PRKCB-ALK (P2:A18) double ALK fusion were identified...This patient with double-ALK fusion was sensitive to crizotinib and a novel PRKCB-ALK fusion was detected.
    DOI:
    10.1016/j.jtho.2019.07.021